Gary Giarratano joins Radient Pharmaceuticals
Takes position of director of North American sales and marketing
Armed with a successful track record in the IVD industry, Giarratano brings more than 20 years of healthcare, sales and marketing leadership experience to the California-based firm. He is recognised for his contributions in new market development for Carcinoembryonic Antigen (CEA), PSA and HPV and led sales for the first company to secure US FDA approval on each of these assays.
‘Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure,’ said Douglas MacLellan, ceo of RPC.
You may also like
Regulatory
Annex 1-compliant freeze drying: a technology supplier’s perspective
GEA Pharma & Healthcare explains how the company has embraced the updated version of Annex 1 and implemented the new changes. Key objectives were to remain compliant and demonstrate to their customers — both current and future — how the amends would be incorporated into ongoing or upcoming projects
Regulatory
Polyplus expands GMP offer with protein production and adds GMP capacity in Belgium
Polyplus (part of Satorius) company, Xpress Biologics, has received a good manufacturing practice (GMP) certification for recombinant protein production and renewed the January 2023 GMP certification for DNA production at the facility located in Belgium